Showing results (1231-1240 of 1,547) with videos related to

Sort By:
Pageof 155
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|May 25, 2021
[Analysis of low-dose computed tomography compliance and related factors among high-risk population of lung cancer in three provinces participating in the cancer screening program in urban China]Y Wen, L Z Yu, L B Du, et al.
Nature Medicine|February 7, 2017
Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samplesLuciano G Martelotto, Timour Baslan, Jude Kendall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2019
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with GlioblastomaPatrick Y Wen, David A Reardon, Terri S Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2024
Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade GliomaSteven Tobochnik, Michael S Regan, Maria K C Dorotan, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
Histopathology|December 31, 2019
Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomasFresia Pareja, Michael S Toss, Felipe C Geyer, et al.
Journal of Neuro-Oncology|October 23, 2014
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomasAndrew D Norden, David Schiff, Manmeet S Ahluwalia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Pageof 155